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PTPN22 is a critical negative regulator of T cell responses. Its promoter gene variant (rs2488457, 1123G>C)
has been reported to be associated with autoimmune diseases. This study analyzed the impact of the PTPN22
variant on transplantation outcomes in a cohort of 663 patients who underwent unrelated HLA-matched
bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor
Program. The recipient C/C genotype versus the recipient G/G genotype resulted in a lower incidence of grade
II-IV acute graft-versus-host disease (hazard ratio [HR], 0.50; 95% conﬁdence interval [CI], 0.29-0.85; P ¼ .01),
as well as a higher incidence of relapse (HR, 1.78; 95% CI, 1.10-2.90; P ¼ .02), as demonstrated on multivariate
analysis. In patients with high-risk disease, the recipient C/C genotype was associated with signiﬁcantly
worse overall survival rates than the recipient G/G genotype (HR, 1.60; 95% CI, 1.02-2.51; P ¼ .04), whereas this
effect was absent in patients with standard-risk disease. In addition, the donor G/C genotype was associated
with a lower incidence of relapse (HR, 0.58; 95% CI, 0.40-0.85), which did not inﬂuence survival. Our ﬁndings
suggest that PTPN22 genotyping could be useful in predicting prognoses and creating therapeutic strategies
for improving the ﬁnal outcomes of allogeneic BMT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION unrelated donor through the Japan Marrow Donor Program
The PTPN22 gene encodes lymphoid speciﬁc phosphatase
(Lyp), expressed inTandB lymphocytes,monocytes, dendritic
cells (DCs), neutrophils, natural killer cells and thymocytes
[1]. PTPN22 is an important negative regulator of T cell acti-
vation involved in the dephosphorylation and inactivation
of TCR-associated kinases. A single nucleotide variant of
the PTPN22 promoter gene, rs2488457 (1123G>C), is asso-
ciated with susceptibility to autoimmune diseases, including
type 1 diabetes and rheumatoid arthritis, in Caucasian and
Asian populations [2-6].
The role of PTPN22 in the immune response, as well as
the association of the PTPN22 variant with autoimmunity,
prompted us to investigate the impact of donor and
recipient 1123G>C variation in the PTPN22 gene on the
clinical outcomes of patients undergoing allogeneic bone
marrow transplantation (BMT) using an HLA allele-matchededgments on page 245.
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12.09.014(JMDP). Our data show that the recipient C/C genotype is
associated with a signiﬁcantly lower incidence of grade II-IV
acute graft-versus-host disease (aGVHD) and a higher inci-
dence of relapse, which predict worse survival outcomes for
patients with high-risk disease.PATIENTS AND METHODS
Patients
PTPN22 genotyping was performed on 663 patients with hematologic
malignancies and their unrelated donors who underwent BMT through the
JMDP with T cellereplete marrow from HLA-A, -B, -C, -DRB1, -DQB1, and
-DPB1 allele-matched donors between January 1993 and December 2007.
This cohort represents 7% (663 of 9229) of all recipients of unrelated BMT in
Japan during the study period. All available data and samples for eligible
patients and their donors were analyzed. None of the patients had a history
of previous transplantation. The study cohort included Asian patients only.
The ﬁnal clinical survey of these patients was completed by November 1,
2008. Diagnoses included acute myelogenous leukemia (AML) in 215
patients (32%), acute lymphoblastic leukemia (ALL) in 164 patients (25%),
chronic myelogenous leukemia (CML) in 118 patients (18%), myelodysplastic
syndrome (MDS) in 89 patients (13%), malignant lymphoma (ML) in 73
patients (11%), andmultiple myeloma in 4 patients (1%) (Tables 1 and 2). The
median follow-up duration in the survivors was 2103 days (range, 124-5136
days); 183 recipients (28%) relapsed or progressed, and 322 (49%) died, 16
(2%) before engraftment. Recipients with AML or ALL in ﬁrst complete
remission, CML in any chronic phase, ML in any complete remission, or MDS
were classiﬁed as having standard-risk disease. All others were classiﬁed asTransplantation.
Table 1
Donor and Recipient Characteristics
Variable Value
Number of cases 663
Recipient age, years, median (range) 34 (1-67)
Donor age, years, median (range) 34 (20-57)
Year of BMT, median (range) 2001 (1993-2007)
Recipient PTPN22 genotype, n (%)
G/G 228 (34)
G/C 331 (50)
C/C 104 (16)
Donor PTPN22 genotype, n (%)
G/G 219 (33)
G/C 324 (49)
C/C 120 (18)
Recipient sex, n (%)
Male 395 (60)
Female 268 (40)
Donor sex, n (%)
Male 420 (63)
Female 243 (37)
Donor/recipient sex match, n (%)
Sex-matched 426 (64)
Female/male 106 (16)
Male/female 131 (20)
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MDS, and lymphoid malignancies included ALL, ML, and multiple myeloma.
All patients received cyclosporine- or tacrolimus-based therapy for GVHD
prophylaxis; none received antieT cell therapy, such as antithymocyte
globulin or ex vivoT cell depletion. All patients and donors provided written
informed consent to participate in molecular studies of this nature at the
time of transplantation, in accordance with the Declaration of Helsinki. This
project was approved by the Institutional Review Board of Kanazawa
University Graduate School of Medicine and the JMDP.
PTPN22 Genotyping
Genotyping of PTPN22 was performed using the TaqMan-Allelic
discrimination method as described previously [7]. The genotyping assay
was conducted in 96-well PCR plates using speciﬁc TaqMan probes for the
PTPN22 gene single nucleotide polymorphism rs2488457 (catalog
C_16027865_10) in a StepOne Plus real-time PCR system (Applied Bio-
systems, Foster City, CA).Table 2
Pretransplant Characteristics
Variable Value
Disease, n (%)
AML 215 (32)
ALL 164 (25)
MDS 89 (13)
ML 73 (11)
CML 118 (18)
Multiple myeloma 4 (1)
Disease stage, n (%)
Standard risk 406 (61)
High risk 257 (39)
ABO matching, n (%)
Major or/and minor mismatch 255 (38)
Major mismatch 145 (22)
Minor mismatch 129 (19)
Bidirectional 19 (3)
Missing 9 (1)
Conditioning regimen, n (%)
Myeloablative 583 (88)
Reduced intensity 80 (12)
With total body irradiation 525 (79)
Pretransplantation CMV serostatus, n (%)
CMV-positive recipient 420 (72)
Missing 80 (12)
GVHD prophylaxis, n (%)
With cyclosporine 376 (57)
With tacrolimus 285 (43)
Missing 2 (0)
TNC,  108/kg, median (range) 5.0 (0.1-316.8)Data Management and Statistical Analysis
Data were collected by the JMDP using a standardized report form.
Follow-up reports were submitted at 100 days and 1 year post-
transplantation, and annually thereafter. Pretransplantation cytomegalo-
virus (CMV) serostatus was routinely tested in recipients only, not in donors.
Engraftment was conﬁrmed by an absolute neutrophil count of >0.5 109/L
for at least 3 consecutive days. Outcome classiﬁcation, including GVHD, did
not change over time.
After data collection, aGVHD and chronic GVHD (cGVHD) were diag-
nosed and graded based on classically deﬁned criteria [8,9]; namely, aGVHD
was deﬁned as GVHD developing within the ﬁrst 100 days post-
transplantation, and cGVHD was deﬁned as GVHD occurring after day 100.
Data using the updated criteria for assessment of GVHD [10,11] were not
available for our cohort. The overall survival (OS) rate was deﬁned as the
number of days from transplantation to death from any cause. Disease
relapse was deﬁned as the number of days from transplantation to disease
relapse. Transplantation-related mortality (TRM) was deﬁned as death
without relapse. Any patients alive at the last follow-up date were censored.
Data on infectious organisms, postmortem changes in causes of death, and
supportive care, including prophylaxis for infections and therapy for GVHD
given on an institutional basis, were not available for this cohort.
All statistical analyses were performed with the EZR software package
(SaitamaMedical Center, Jichi Medical University), a graphical user interface
for R version 2.13.0 (R Foundation for Statistical Computing, Vienna, Austria)
[12], as described previously [13]. The probability of OS was calculated using
the Kaplan-Meier method and compared using the log-rank test. The
probabilities of TRM, disease relapse, aGVHD, cGVHD, and engraftment were
compared using the Gray test [14] and analyzed using cumulative incidence
analysis [15], considering relapse, death without disease relapse, death
without aGVHD, death without cGVHD, and death without engraftment as
respective competing risks. Variables included recipient age at the time of
BMT, sex, pretransplantation CMV serostatus, disease characteristics (ie,
disease type, disease lineage, and disease risk at transplantation), donor
characteristics (ie, age, sex, sex compatibility, and ABO compatibility),
transplant characteristics (ie, conventional or reduced-intensity condi-
tioning [16], total body irradiationecontaining regimens, tacrolimus versus
cyclosporine, and total nucleated cell count harvested per recipient weight),
and year of transplantation. The median was used as the cutoff point for
continuous variables. The c2 test and Mann-Whitney U test were used to
compare data between 2 groups. The Hardy-Weinberg equilibrium for the
PTPN22 gene variant was determined using the Haploview program [17].
Multivariate Cox models were used to evaluate the hazard ratio (HR)
associated with the PTPN22 variation. Covariates found to be signiﬁcant in
the univariate analyses (P  .10) were used to adjust the HR. For both the
univariate and multivariate analyses, P values were 2-sided, and P  .05 was
considered to indicate statistical signiﬁcance.
RESULTS
Frequencies of PTPN22 Genotypes
The rs2488457 single nucleotide polymorphism in the
PTPN22 gene was genotyped in 663 unrelated BMT
donorerecipient pairs (Table 1). The genotype frequencies of
G/G, G/C, and C/C were 34%, 50%, and 16% in recipients and
33%, 49%, and 18% in donors, respectively. These results are in
accordance with the Hardy-Weinberg equilibrium (P ¼ .49)
and similar to HapMap data reported in the Japanese pop-
ulation [5]. Donor and recipient PTPN22 genotype did not
signiﬁcantly inﬂuence the cumulative incidence of engraft-
ment (data not shown).
Effects of Recipient PTPN22 Genotype on Transplantation
Outcomes
Transplantation outcomes according to PTPN22 genotype
are summarized in Table 3. Recipient C/C genotype was
signiﬁcantly associated with a lower incidence of grade II-IV
aGVHD (18%) compared with recipient G/G (33%; P ¼ .009)
and G/C (35%; P ¼ .02) genotypes (Figure 1A), suggesting the
homozygous recessive effects of the C allele. We randomly
split the study cohort into 2 subcohorts to test the validity of
these associations. Subcohort 1 included 116 (35%) recipient
C/C, 164 (49%) recipient G/C, and 52 (16%) recipient G/G
genotypes, and subcohort 2 comprised 116 (35%) recipient G/
G, 167 (50%) recipient G/C, and 52 (16%) recipient C/C
Table 3
Univariate Analysis of Associations between PTPN22 Variations and Clinical Outcomes after BMT
Variable Number 5-Year
OS, %
P 5-Year
TRM, %
P 5-Year
Relapse, %
P Grade II-IV
aGVHD, %
P Grade III-IV
aGVHD, %
P Chronic
GVHD, %
P
Recipient PTPN22 genotype
G/G 228 48 25 28 33 11 43
G/C 331 50 .73 28 .67 27 .75 35 .69 15 .26 47 .36
C/C 104 48 .64 19 .43 40 .06 18 .009 6 .18 42 .79
Donor PTPN22 genotype
G/G 219 48 22 34 32 13 42
G/C 324 48 .59 30 .08 27 .04 31 .73 11 .57 45 .42
C/C 120 53 .38 21 .62 29 .35 33 .85 14 .79 49 .24
Signiﬁcant values (P  .05) are in bold.
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detect the difference between the recipient C/C genotype and
recipient G/C or G/G genotype in both subcohort analyses.
The association between recipient C/C genotype and a lower
incidence of grade II-IV aGVHD remained positive in the
analyses of subcohort 1 (P ¼ .04) and subcohort 2 (P ¼ .03)
(Supplemental Figure 1).
In addition, the recipient C/C genotype was associated
with a higher incidence of relapse (40%) compared with that
seen in the recipient G/G (28%; P¼ .06) and G/C (27%; P¼ .02)
genotypes (Figure 1B). This difference had no signiﬁcant
inﬂuence on OS or TRM, however.
In a comparison of the impact of the PTPN22 genotype in
recipients with standard-risk disease and those with high-
risk disease to investigate the signiﬁcant effect of recipient
genotype on relapse rate, the effect of recipient genotype on
the incidence of grade II-IV aGVHD appeared unchanged. In
patients with high-risk disease, the incidence of grade II-IV
aGVHD was 33% in those with the recipient G/G genotype,
38% in those with the G/C genotype, and 17% in those with
the C/C genotype (P ¼ .10). In patients with standard risk
disease, these values were 33%, 34%, and 18% (P ¼ .09),
respectively. In patients with high-risk disease, the 5-year
cumulative incidence of relapse associated with the recip-
ient C/C genotype was as high as 50%, which was not
signiﬁcantly different from that in those with the recipient
G/G (39%; P¼ .28) and G/C (35%; P¼ .14) genotypes; however,
this likely contributed to a signiﬁcantly lower 5-year OS rate
associated with the recipient C/C genotype (20%) compared
with the recipient G/C (37%; P ¼ .02) and G/G genotypes
(32%; P ¼ .05) (Figure 2A). In patients with standard-risk
disease, the 5-year cumulative incidence of relapse was
32% in those with the recipient C/C genotype, 22% in thoseFigure 1. Estimated cumulative incidence curves of grade II-IV aGVHD (A) and relapse
G/G genotype; dashed lines, the recipient G/C genotype; and dotted lines, the recipiewith the G/G phenotype (P ¼ .23), and 32% in those with the
G/C genotype (P ¼ .17), and there were no signiﬁcant differ-
ences in OS rate (Figure 2B).
After adjusting for clinical factors in the multivariate
model, recipient C/C genotype remained statistically signiﬁ-
cant compared with the recipient G/G genotype with respect
to the development of grade II-IV aGVHD (HR, 0.50; 95%
conﬁdence interval [CI], 0.29-0.85; P ¼ .01; Table 4) and
relapse (HR, 1.78; 95% CI, 1.10-2.90; P ¼ .02; Table 5).
Although analysis of the entire cohort revealed no consid-
erable effects of the PTPN22 genotype on OS rates (Table 5),
compared with recipient G/G genotype. recipient C/C geno-
type was associated with signiﬁcantly lower OS in patients
with high-risk disease (HR, 1.60; 95% CI, 1.02-2.51; P ¼ .04;
Table 6) and with a signiﬁcantly higher incidence of relapse
in patients with standard-risk disease (HR, 2.02; 95% CI, 1.02-
4.00; P ¼ .04). No effects of recipient C/C genotype on OS
rates were seen in patients with standard-risk disease.
The increased risk of relapse associated with recipient C/C
genotype could be outweighed by the decreased risk of grade
II-IV aGVHD, given that the absence of grade II-IV aGVHDwas
closely linked to the higher incidence of relapse (31% versus
19% at 5 years; P¼ .01) in the landmark analysis completed at
day 60, in agreement with a previous report [18]. Conse-
quently, we analyzed the impact of recipient PTPN22
genotype on relapse according to the development of grade
II-IV aGVHD. The landmark time for aGVHD analysis was
chosen as day 60 post-BMT, as in a previous study [18],
because more than 90% of patients who develop grade II-IV
aGVHD do so within 60 days after transplantation [19]. In
patients who developed grade II-IV aGVHD before day 60,
the cumulative incidence of relapse was higher in those with
the recipient C/C genotype (47% at 5 years) compared with(B) according to recipient PTPN22 genotype. Solid lines represent the recipient
nt C/C genotype.
Figure 2. Kaplan-Meier analysis of OS after BMT according to the recipient PTPN22 genotype in patients with high-risk disease (A) and those with standard-risk
disease (B). Solid lines represent the recipient G/G genotype; dashed lines, the recipient G/C genotype; and dotted lines, the recipient C/C genotype.
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genotype. The increased incidence of relapse associated with
the recipient C/C genotype was conﬁrmed on multivariate
analysis, with an HR for relapse for the recipient C/C geno-
type versus G/G genotype as high as 4.5 (95% CI, 1.56-12.78;
P ¼ .005). In patients who survived more than 60 days
without developing grade II-IV aGVHD, the 5-year cumula-
tive incidence of relapse was higher in those with the
recipient C/C genotype (39%) than in those with the recipient
G/G (30%; P ¼ .22), G/C (28%; P ¼ .24), and G/G or G/C
genotypes (30%; P ¼ .21). After adjustment of covariates
using the multivariate model, the increased incidence of
relapse associated with the recipient C/C genotype was close
to being signiﬁcant compared with recipient G/G (HR, 1.79;
95% CI, 0.98-3.26; P ¼ .06) and G/G or G/C (HR, 1.64; 95% CI,
0.99-2.71; P ¼ .06) genotypes. Accordingly, the effects of
recipient C/C genotype in increasing the incidence of relapse
are considered independently signiﬁcant irrespective of the
development of grade II-IV aGVHD.
Effects of Donor PTPN22 Genotype on Transplantation
Outcomes
Compared with donor G/G genotype, donor G/C genotype
was correlated with a signiﬁcantly lower incidence of relapse
(27% versus 34%; P ¼ .04) and with a trend toward increased
TRM (30% versus 22%; P ¼ .08). The effects of the lower
relapse rate associated with the donor G/C genotype were
also evident in the multivariate analysis (HR, 0.58; 95% CI,
0.40-0.85; P ¼ .005; Table 5). The effects of donor G/C
genotype on relapse and TRM had no signiﬁcant impact on
OS; this also held true in the analysis performed according to
disease risk (data not shown).Table 4
Multivariate Analysis of the Association between PTPN22 Variations and GVHD aft
Variable Grade II-IV aGVHD
Adjusted HR 95%
Recipient PTPN22 genotype, G/C (331) versus G/G (n ¼ 228) 1.64 0.79
Recipient PTPN22 genotype, C/C (104) versus G/G (n ¼ 228) 0.50 0.29
Donor PTPN22 genotype, G/C (324) versus G/G (n ¼ 219) 0.95 0.70
Donor PTPN22 genotype, C/C (120) versus G/G (n ¼ 219) 1.08 0.72
Recipient age 34 years
Total body irradiationecontaining conditioning regimen
High-risk disease
Year of BMT 2001 or later
Covariates identiﬁed as signiﬁcant in the univariate analyses (P  .10) were used t
bold.DISCUSSION
In our study cohort, the recipient C/C genotype at the
rs2488457 (1123G>C) variant of the PTPN22 promoter gene
was associated with a lower incidence of grade II-IV aGVHD
and a higher incidence of relapse after unrelated HLA-
matched BMT performed through the JMDP. The recipient
C/C genotype negatively affected OS in patients with high-
risk disease, but not in those with standard-risk disease. In
addition, the donor G/C genotype predicted a lower inci-
dence of relapse, but had no signiﬁcant impact on OS irre-
spective of disease risk.
Previous studies have identiﬁed 4 variations in the PTPN22
gene associated with susceptibility to autoimmune diseases.
The þ1858C>T variation (rs2476601) is in near-perfect
disequilibrium with rs6679677 [20] and is closely linked to
the1123G>C variation (rs2488457) analyzed in the present
study [2,5,21-23]. The þ1858C>T variation was ﬁrst identi-
ﬁed as associatedwith type 1 diabetes using a candidate gene
approach [24]. Subsequent studies have conﬁrmed this
ﬁnding, as well as the variation’s association with other
autoimmune diseases, including Crohn’s disease, ulcerative
colitis, rheumatoid arthritis, Graves disease, autoimmune
thyroid disease, vitiligo, alopecia, systemic lupus eryth-
ematosus, and acute allograft rejection [25]. The þ1858C>T
variation is not polymorphic in the Asian population [5];
instead, the 1123G>C variation is associated with type 1
diabetes and rheumatoid arthritis [2]. In addition,
the1123G>C variation is more closely associated with type
1 diabetes than the þ1858C>T variation in the European
population [5]. The remaining variation, þ788G>A (Lyp-
R263Q, rs33996649), is associated with ulcerative colitis,
rheumatoid arthritis, and systemic lupus erythematosus [26].er BMT
Grade III-IV aGVHD cGVHD
CI P Adjusted HR 95% CI P Adjusted HR 95% CI P
-1.44 .68 1.32 0.80-2.18 .28 1.08 0.81-1.44 .59
-0.85 .01 0.54 0.22-1.34 .18 0.89 0.58-1.34 .59
-1.30 .76 0.81 0.48-1.36 .42 1.13 0.84-1.53 .42
-1.61 .72 1.10 0.59-2.07 .76 1.33 0.93-1.90 .11
1.31 1.00-1.72 .05
1.44 1.01-2.06 .05
0.75 0.56-0.99 .05
0.69 0.42-1.11 .12
o adjust the HR for the PTPN22 genotype. Signiﬁcant results (P  .05) are in
Table 5
Multivariate Analysis of the Association between PTPN22 Variations and Prognostic Outcomes after Transplantation
Variable OS TRM Relapse
Adjusted HR 95% CI P Adjusted HR 95% CI P Adjusted HR 95% CI P
Recipient PTPN22 genotype, G/C (331) versus G/G
(n ¼ 228)
0.94 0.71-1.25 .69 0.84 0.55-1.28 .84 1.08 0.73-1.64 .71
Recipient PTPN22 genotype, C/C (104) versus G/G
(n ¼ 228)
1.03 0.68-1.56 .87 0.67 0.33-1.35 .27 1.78 1.10-2.90 .02
Donor PTPN22 genotype, G/C (324) versus G/G
(n ¼ 219)
0.91 0.68-1.21 .51 1.24 0.78-1.97 .37 0.58 0.40-0.85 .005
Donor PTPN22 genotype, C/C (120) versus G/G
(n ¼ 219)
0.78 0.53-1.15 .21 1.08 0.60-1.97 .79 0.64 0.40-1.04 .07
Minor ABO incompatibility 1.74 1.10-2.77 .002
Recipient age 34 years 1.61 1.23-2.10 .001 2.21 1.45-3.37 <.001
CMV-positive recipient 2.15 1.13-4.08 .002 1.49 0.95-2.34 .08
Conventional conditioning regimen 1.33 0.64-2.78 .45
Total body irradiationecontaining conditioning
regimen
0.95 0.60-1.52 .84
High-risk disease 2.08 1.60-2.69 <.001 1.75 1.14-2.70 .01 1.76 1.22-2.53 .003
Female donor/male recipient 0.67 0.40-1.11 .12
TNC  5.0  108/kg 0.92 0.63-1.36 .69
Year of BMT 2001 or later 0.98 0.74-1.31 .90
Covariates identiﬁed as signiﬁcant in the univariate analyses (P  .10) were used to adjust the HR for the PTPN22 genotype. Signiﬁcant results (P  .05) are in
bold.
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have validated the association of these variations with type
1 diabetes, inﬂammatory bowel disease, Graves disease,
rheumatoid arthritis, and systemic lupus erythematosus [27].
Experimental evidence has demonstrated thatþ1858C>T
(Lyp-R620W, rs2476601) and þ788G>A (Lyp-R263Q,
rs33996649) are functional [28,29]. Lyp-Trp620 (þ1858T) is
associated mainly with an increased risk of autoimmune
diseases and impaired constitutive biding of Lyp with c-SrcTable 6
Impact of Recipient PTPN22 Genotype on OS and TRM According to Disease Risk in
Variable OS
Adjusted HR 95%
Patients with high-risk disease
Recipient PTPN22 genotype, G/C (128) versus G/G
(n ¼ 89)
0.95 0.57-
Recipient PTPN22 genotype, C/C (40) versus G/G (n ¼ 89) 1.60 1.02
Donor PTPN22 genotype, G/C (186) versus G/G (n ¼ 142) 0.90 0.63-
Donor PTPN22 genotype, C/C (69) versus G/G (n ¼ 142) 0.81 0.51-
Minor ABO incompatibility
Recipient age 34 years 1.76 1.28
CMV-positive recipient
Conventional conditioning regimen
Total body irradiationecontaining conditioning regimen
Female donor/male recipient
TNC  5.0  108/kg
Year of BMT 2001 or later 0.93 0.67-
Patients with standard-risk disease
Recipient PTPN22 genotype, G/C (199) versus G/G
(n ¼ 138)
0.96 0.67-
Recipient PTPN22 genotype, C/C (60) versus G/G
(n ¼ 138)
0.84 0.49-
Donor PTPN22 genotype, G/C (186) versus G/G (n ¼ 142) 1.17 0.82-
Donor PTPN22 genotype, C/C (69) versus G/G (n ¼ 142) 0.83 0.50-
Minor ABO incompatibility
Recipient age 34 years 1.68 1.20
CMV-positive recipient
Conventional conditioning regimen
Total body irradiationecontaining conditioning regimen
Female donor/male recipient
TNC  5.0  108/kg
Year of BMT 2001 or later 1.24 0.88-
Covariates identiﬁed as signiﬁcant in the univariate analyses (P .10) were used to atyrosine kinase (Csk) [30]. The inability of Lyp-Trp620 to bind
Csk results in a less efﬁcient inhibition of TCR signaling,
because Lyp and Csk concertedly down-regulate TCR
signaling [28]. Previous studies in cell lines and primary
human cells have shown conﬂicting results, however [28].
Lyp-Trp620epositive primary human T cells were found to
produce less IL-2 on TCR signaling, and Lyp-Trp620 more
potently reduced TCR signaling in a dose-dependent manner,
suggesting a gain-of-function mutation [30]. Conversely, thethe Multivariate Analysis
TRM Relapse
CI P Adjusted HR 95% CI P Adjusted HR 95% CI P
1.35 .78 0.89 0.47-1.69 .73 1.05 0.60-1.84 .87
-2.51 .04 0.92 0.36-2.34 .85 1.51 0.75-3.05 .25
1.28 .55 1.29 0.60-2.80 .51 0.53 0.31-0.91 .02
1.29 .37 1.54 0.64-3.75 .34 0.56 0.29-1.11 .10
2.32 1.14-4.73 .02
-2.43 .001 2.43 1.28-4.59 .006
1.33 0.58-3.06 .50 1.26 0.66-2.41 .49
1.33 0.35-5.14 .68
1.80 0.53-6.15 .35
0.85 0.41-1.78 .67
1.11 0.61-2.03 .74
1.29 .67
1.37 .81 0.78 0.46-1.34 .37 1.12 0.63-2.00 .70
1.43 .52 0.51 0.18-1.41 .19 2.02 1.02-4.00 .04
1.69 .39 1.23 0.67-2.24 .51 0.65 0.39-1.10 .11
1.38 .48 0.81 0.35-1.86 .62 0.74 0.38-1.45 .39
1.39 0.72-2.71 .33
-2.36 .003 2.04 1.16-3.59 .01
3.45 1.19-9.96 .02 1.74 0.90-3.39 .10
1.10 0.46-2.64 .83
0.79 0.45-1.36 .39
0.51 0.25-1.07 .08
0.84 0.50-1.39 .50
1.74 .23
djust the HR for the PTPN22 genotype. Signiﬁcant values (P .05) are in bold.
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risk of autoimmune diseases, reportedly results in loss of
function [29].
The mechanisms through which the recipient 1123C
allele of the PTPN22 gene affects the incidence of aGVHD and
disease relapse remain unclear. Previous reports of the
number of regulatory T cells (Tregs) increasing inversely with
the level of PTPN22 in the thymus [31] and of thymus-derived
Tregs operating to prevent aGVHD and promote disease
relapse [32] suggest the hypothesis that in transplant recipi-
ents, the PTPN221123G>C variant inﬂuences the production
of Tregs from the thymus. This hypothesis may be supported
by the fact that the PTPN22 gene has a functional var-
iant,þ1858C>T, that is closely linked to the1123G>C variant
[2,5,21-23], and that the minor þ1858T allele functionally
inhibits TCR signaling more potently than the major þ1858C
allele [30]. Hyporesponsive TCR signaling might lead to
increasedTregproductionby thethymus,giventhatdecreased
TCR signaling can promote the development of intrathymic
Tregs [33]. Thus, an increased number of Tregs in relation to
the recipient1123C/C genotypemight prevent aGVHD at the
expense of decreased graft-versus-tumor effects. These
hypotheses must be considered speculative, however, given
the lack of functional data on the 1123G>C variant. Eluci-
dating the role of the PTPN22 1123G>C variant in Treg
production will provide useful information in this regard.
A second possible mechanism includes the involvement
of host DCs, which are critical for the initiation of aGVHD
[34]. This possibility may be supported by a recent report
indicating that the PTPN22þ1858C>T variant plays key roles
in antigen receptor signaling of DCs [28].
Why the PTPN22 1123G>C genotype displays different
behaviors in the donor and recipient genotypes is obscure. Of
note, the donor heterozygous 1123G/C genotype was asso-
ciated with a reduced incidence of relapse, which could be
attributed to increased graft-versus-tumor effects owing to
donor G/C genotype. The effects of the heterozygous1123G/
C genotype on autoimmunity may be related to the associa-
tion between this genotype and increased risk of developing
autoimmune diseases, including type 1 diabetes and rheu-
matoid arthritis, in Asian populations [2,3,5]. However
the present study showed no gene dose responses, and
whether this phenomenon reﬂects a molecular heterosis is
unclear [3,5,35].
The lack of considerable survival advantage in relation to
donor PTPN22 genotype may suggest that the beneﬁcial
effects of PTPN22 genotyping are limited. However, deter-
mination of the recipient PTPN22 genotype before trans-
plantation might provide a recipient harboring the PTPN22
G/C or G/G genotype an opportunity to avoid the risk
of aGVHD by favoring a bone marrow or cord blood HLA-
matched graft over a peripheral blood stem cell (PBSC)
or HLA-mismatched graft. Conversely, a PBSC or HLA-
mismatched graft, along with minimal aGVHD prophylaxis,
could be acceptable for a recipient harboring the PTPN22 C/C
genotype. In addition, a recipient with the 1123G/G or G/C
genotype may require a bone marrow or cord blood graft to
avoid aGVHD. This may apply especially to recipients with
a benign disease, such as severe aplastic anemia or primary
immunodeﬁciency, in whom relapse does not matter.
A previous study investigated the impact of the
PTPN22 þ1858C>T variant on transplantation outcomes in
a cohort of European patients who underwent hematopoietic
stem cell transplantation for hematologic malignancies [36].
Although a relatively small number of patients were includedin that analysis, the authors found that the donor þ1858C/C
genotype was consistently linked with severe bacterial infec-
tions [36]. Another study [37] showed that recipientedonor
pairs carrying 2 or more PTPN22 1858T alleles were at
increased risk for grade III-IV aGVHD, but not for grade II-IV
aGVHD. Although determining whether such associations
are also present in Japanese patients is not possible, because
theþ1858C>Tvariant isnotpolymorphic inAsianpopulations
[2,3,5], these resultsmight support involvementof thePTPN22
gene in the pathophysiology of aGVHD, as suggested in the
present study.
In conclusion, our data suggest that the speciﬁc PTPN22
variant affects prognosis after unrelated donor BMT. Thus,
PTPN22 genotyping in transplant donors and recipients can
be a useful tool for evaluating pretransplantation risk and, in
combination with other known risk factors, can form the
basis for tailoring individual treatment strategies. Nonethe-
less, care should be taken when drawing conclusions from
our data; experimental evidence is needed to verify the
effects of PTPN22 variations. Moreover, the present study did
not include adjustment for multiple testing, because the
analyses were conducted in an exploratory context, and thus
the interpretation of analyses in the subgroups should be
taken into account. Finally, transplantation outcomes,
including aGVHD and relapse are multifactorial, and single
polymorphisms in one cytokine gene are unlikely to deter-
mine themajority of outcomes. Further studies are needed to
ascertain whether the ﬁndings of this study can be extended
to other stem cell sources or to HLA-mismatched trans-
plantation, and to validate these data in other ethnic groups.
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